Chengdu Olymvax Biopharmaceuticals Inc.
Shanghai Stock ExchangeTotal Valuation
Chengdu Olymvax Biopharmaceuticals Inc. carries a market capitalization of 12.50B, placing it among publicly traded companies globally. Its enterprise value stands at 6.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.50B |
| Enterprise Value | 6.57B |
Share Statistics
Chengdu Olymvax Biopharmaceuticals Inc. currently has 405.93M shares outstanding.
| Shares Outstanding | 405.93M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Chengdu Olymvax Biopharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 102.85. The price-to-sales ratio is 9.52, and the price-to-book ratio stands at 19.70.
| PE Ratio | 102.85 |
| PS Ratio | 9.52 |
| PB Ratio | 19.70 |
| P/TBV Ratio | 10.15 |
| P/FCF Ratio | 46.17 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Chengdu Olymvax Biopharmaceuticals Inc. trades at an EV/EBITDA multiple of 65.22 and an EV/FCF ratio of 43.21. The EV/Sales ratio of 9.83 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 65.22 provides insight into valuation relative to core operating earnings.
| EV / Sales | 9.83 |
| EV / EBITDA | 65.22 |
| EV / EBIT | 65.22 |
| EV / FCF | 43.21 |
Financial Position
Chengdu Olymvax Biopharmaceuticals Inc. maintains a current ratio of 1.61, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.54, indicating elevated leverage, while an interest coverage ratio of 6.58 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.61 |
| Quick Ratio | 0.36 |
| Debt / Equity | 42.54 |
| Debt / EBITDA | 3.95 |
| Interest Coverage | 6.58 |
Financial Efficiency
Chengdu Olymvax Biopharmaceuticals Inc. posts a return on equity of 20.97 and a return on invested capital of 7.59.
| Return on Equity (ROE) | 20.97 |
| Return on Assets (ROA) | 3.54 |
| Return on Invested Capital (ROIC) | 7.59 |
| Return on Capital Employed (ROCE) | 11.47 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.51 |
Taxes
Over the trailing twelve months, Chengdu Olymvax Biopharmaceuticals Inc. has paid 5.05M in income taxes, reflecting an effective tax rate of 7.46.
| Income Tax | 5.05M |
| Effective Tax Rate | 7.46 |
Stock Price Statistics
Chengdu Olymvax Biopharmaceuticals Inc.'s stock has gained approximately 70.8264% over the past 52 weeks. The 50-day moving average sits at 32.40, while the 200-day moving average is 27.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | 70.8264% |
| 50-Day Moving Average | 32.40 |
| 200-Day Moving Average | 27.79 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chengdu Olymvax Biopharmaceuticals Inc. generated 668.43M in revenue and converted that into 61.90M in net income, yielding earnings per share of 0.15. EBITDA reached 100.75M, while operating income came in at 100.75M.
| Revenue | 668.43M |
| Gross Profit | 627.14M |
| Operating Income | 100.75M |
| Pretax Income | 67.71M |
| Net Income | 61.90M |
| EBITDA | 100.75M |
| EBIT | 100.75M |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
Chengdu Olymvax Biopharmaceuticals Inc. holds 201.92M in cash and equivalents against 397.54M in total debt, resulting in a net debt position of 139.92M. Total book value stands at 323.24M, with working capital of 345.42M providing operational flexibility.
| Cash & Cash Equivalents | 201.92M |
| Total Debt | 397.54M |
| Net Debt | 139.92M |
| Equity (Book Value) | 323.24M |
| Book Value Per Share | 0.80 |
| Working Capital | 345.42M |
Cash Flow
After subtracting -137.90M in capital expenditures, free cash flow totaled -137.90M - equivalent to -0.34 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -137.90M |
| Free Cash Flow | -137.90M |
| FCF Per Share | -0.34 |
Margins
Chengdu Olymvax Biopharmaceuticals Inc. operates with a gross margin of 93.82, reflecting its pricing power and cost economics. The operating margin of 15.07 and net profit margin of 9.26 provide insight into operational efficiency.
| Gross Margin | 93.82 |
| Operating Margin | 15.07 |
| Pretax Margin | 10.13 |
| Profit Margin | 9.26 |
| EBITDA Margin | 15.07 |
Dividends & Yields
The company's payout ratio of 26.48 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.04 |
| Dividend Yield | N/A |
| Payout Ratio | 26.48 |
| Shareholder Yield | -0.24 |
| FCF Yield | 2.17 |
Scores
Chengdu Olymvax Biopharmaceuticals Inc. posts an Altman Z-Score of 5.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.09 |